| Ytd | 52.64% | |
| 1y | 127.96% |
| Open | 6.96 | Prev Close | 6.77 | Low | 6.79 | High | 7.05 | Mkt Cap | 87.03M |
| Vol | 56.73K | Avg Vol | 107.27K | EPS | -0.78 | P/E | N/A | Forward P/E | -23.30 |
| Beta | 1.38 | Short Ratio | 1.54 | Inst. Own | 1.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.57 | 200-d Avg | 6.43 | 1yr Est | 7.50 |
NRXS News
NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both heal
CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE
MariMed (OTCMKTS:MRMD - Get Free Report) and NeurAxis (NASDAQ: NRXS - Get Free Report) are both smal
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE
NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplet
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 T
KODK and NRXS are worth watching for their growth.
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.19) per share which beat the analyst consensus
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE A
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday'
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE A
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.18) per share which beat the analyst consensus
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE A
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.17) per share which beat the analyst consensus
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
The new CPT code reflects the latest efficacious medical care available to patients, facilitating ad
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the
NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical techno
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consens
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology comp